Disseminated tumor cells of breast cancer patients: A strong prognostic factor for distant and local relapse

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3306-3311

  Bidard, Francois Clément ^a   Vincent Salomon, Anne ^b   Gomme, Stéphanie ^b   Nos, Claude ^c   De Rycke, Yann ^b   Thiery, Jean Paul ^d   Sigal Zafrani, Brigitte ^b   Mignot, Laurent ^a   Sastre Garau, Xavier ^b   Pierga, Jean Yves ^a,c,e  

^a Medical Imaging Department   (France)

^b Department of Pathology ^*  (France)

^c INSTITUT CURIE   (France)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e LIPADE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; KERATIN;

AGED; ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; ADULT; BONE MARROW; BREAST TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR EMBOLISM; TUMOR RECURRENCE;

ADULT; AGED; BONE MARROW; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 50349096764     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4749     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
2. Goldhirsch A.Wood W, Gelber R, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
3. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
4. Fidler I J. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
5. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
6. Slade MJ, Coombes RC. The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 2007;4:30-41.
7. Benoy IH, Elst H, Philips M, et al. Real-time RT- PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006;94: 672-80.
8. Braun S. Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
9. Borgen E, Beiske K, Trachsel S, et al. Immunocyto- chemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998;185:427-34.
10. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. The European ISHAGE Working Group for Standardization of Tumor Cell Detection. Cytotherapy 1999;1:377-88.
11. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-78.
12. Naume B, Wiedswang G, Borgen E, et al. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 2004;10: 3091 -7.
13. Pierga JY, Bonneton C, Magdelenat H, et al. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer 2003;89:539-45.
14. Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004;10:1392-400.
15. Pierga JY, Bonneton C, Magdelenat H, et al. Real-time quantitative PCR determination of uroki- nase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 2005; 114:291 -8.
16. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
17. Hormbrey E, Han C, Roberts A, McGrouther DA, Harris AL. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res 2003;9:4332-9.
18. Picardo M, Schor SL, Grey AM, et al. Migration stimulating activity in serum of breast cancer patients. Lancet 1991;337:130-3.
19. Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18: 80-6.
20. Slade MJ, Singh A, Smith BM, et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. Int J Cancer 2005;114:94-100.
21. Wiedswang G, Borgen E, Karesen R, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004;10: 5342-8.
22. Wiedswang G, Borgen E, Karesen R, et al. Clinical relevance of detection of isolated tumor cells in bone marrow in early breast cancer. J Clin Oncol 2003;21: 3469-78.
23. Naume B, Zhao X, Synnestvedt M, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 2007;1:160-71.
24. Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007;25:5194-202.
25. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
26. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006;17:945-51.
27. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008;19: 496-500.
28. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
29. Cristofanilli M, Broglio KR, GuarneriV, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471 -9.
30. Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005;103:884-91.